RT Journal Article
SR Electronic
T1 Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.19.21268038
DO 10.1101/2021.12.19.21268038
A1 Pearson, Carl A. B.
A1 Silal, Sheetal P.
A1 Li, Michael W.Z.
A1 Dushoff, Jonathan
A1 Bolker, Benjamin M.
A1 Abbott, Sam
A1 van Schalkwyk, Cari
A1 Davies, Nicholas G.
A1 Barnard, Rosanna C.
A1 Edmunds, W. John
A1 Bingham, Jeremy
A1 Meyer-Rath, Gesine
A1 Jamieson, Lise
A1 Glass, Allison
A1 Wolter, Nicole
A1 Govender, Nevashan
A1 Stevens, Wendy S.
A1 Scott, Lesley
A1 Mlisana, Koleka
A1 Moultrie, Harry
A1 Pulliam, Juliet R. C.
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268038.abstract
AB A new SARS-CoV-2 variant of concern, Omicron (B.1.1.529), has been identified based on genomic sequencing and epidemiological data in South Africa. Presumptive Omicron cases in South Africa have grown extremely rapidly, despite high prior exposure and moderate vaccination coverage. The available evidence suggests that Omicron spread is at least in part due to evasion of this immune protection, though Omicron may also exhibit higher intrinsic transmissibility. Using detailed laboratory and epidemiological data from South Africa, we estimate the constraints on these two characteristics of the new variant and their relationship. Our estimates and associated uncertainties provide essential information to inform projection and scenario modeling analyses, which are crucial planning tools for governments around the world.One Sentence Summary We report a region of plausibility for the relative transmissibility and immune escape characteristics of the SARS-CoV-2 Omicron variant estimated by integrating laboratory and epidemiological data from South Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCABP is supported by the Bill & Melinda Gates Foundation (NTD Modelling Consortium OPP1184344). SPS is supported by Wellcome Trust grant 214236/Z/18Z. SPS, GMR, LJ, and JRCP are supported by the Bill & Melinda Gates Foundation (Investment 035464). JD is supported by Canadian Institutes for Health Research. BMB is supported by Natural Sciences and Engineering Research Council (NSERC) Discovery grants and the CANMOD network, funded through an NSERC Emerging Infectious Diseases Modelling Initiative (EIDM) grant. NGD is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation. WJE and RCB are supported by the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688). JB and JRCP are supported by Wellcome Trust grant 221003/Z/20/Z in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom. CvS, JB, and JRCP are supported by the South African Department of Science and Innovation and the National Research Foundation. Any opinion, finding, and conclusion or recommendation expressed in this material is that of the authors and the NRF does not accept any liability in this regard. WSS and LS are supported by the South African Medical Research Council with funds received from the Department of Science and Innovation and the Bill & Melinda Gates Foundation (OPP1171455).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has received ethical clearance from University of the Witwatersrand (Clearance certificate number M210752, formerly M160667) and approval under reciprocal review from Stellenbosch University (Project ID 19330, Ethics Reference Number N20/11/074_RECIP_WITS_M160667_COVID-19).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code for all the analyses will soon be available from https://github.com/SACEMA/omicronSA. Data necessary to conduct the analysis is either included in the repository, fetched by that code from publicly available sources, or available upon formal request. Aside from the data made available in the repository, the non-public South African data are covered by a non-disclosure agreement and cannot be released by the authors. Requests for these data must be made in writing to the National Institute for Communicable Diseases, South Africa.